These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1407230)

  • 1. [Selegine in Parkinson's disease--current status in research and therapy. 2nd Internation Congress of Movement Disorders. Munich, 23 June 1992].
    Nervenarzt; 1992 Sep; 63(9 Suppl):1-4. PubMed ID: 1407230
    [No Abstract]   [Full Text] [Related]  

  • 2. [Selegiline in the therapy of Parkinson's disease].
    Stojiljković MP; Dragojević-Simić V; Bosković B
    Vojnosanit Pregl; 1992; 49(4):357-68. PubMed ID: 1481452
    [No Abstract]   [Full Text] [Related]  

  • 3. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW; Mytilineou C; Tatton W
    Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract]   [Full Text] [Related]  

  • 4. Selegiline (Eldepryl) for Parkinson's disease.
    Waters CH
    West J Med; 1991 Jul; 155(1):68-9. PubMed ID: 1908608
    [No Abstract]   [Full Text] [Related]  

  • 5. Selegiline and mortality in Parkinson's disease: another view.
    Lees AJ; Head J; Shlomo YB
    Ann Neurol; 1997 Feb; 41(2):282-3. PubMed ID: 9029081
    [No Abstract]   [Full Text] [Related]  

  • 6. Selegiline and Parkinson's disease. Protective and symptomatic considerations.
    Golbe LI; Langston JW; Shoulson I
    Drugs; 1990 May; 39(5):646-51. PubMed ID: 2112994
    [No Abstract]   [Full Text] [Related]  

  • 7. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies.
    Langston JW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 61-6; discussion 67-9. PubMed ID: 2120617
    [No Abstract]   [Full Text] [Related]  

  • 9. Selegiline in the treatment of Parkinson's disease.
    Robin DW
    Am J Med Sci; 1991 Dec; 302(6):392-5. PubMed ID: 1772127
    [No Abstract]   [Full Text] [Related]  

  • 10. Selegiline and Parkinson's disease: it's déjà vu-again.
    Langston JW; Tanner CM
    Neurology; 2000 Dec; 55(12):1770-1. PubMed ID: 11134369
    [No Abstract]   [Full Text] [Related]  

  • 11. [A new drug for Parkinson's disease: selegiline (Eldeprine). Copenhagen, January 26-27, 1989].
    D'Anglejan-Chatillon J
    Rev Prat; 1989 Oct; 39(22):1978. PubMed ID: 2510243
    [No Abstract]   [Full Text] [Related]  

  • 12. Pergolide and selegiline for Parkinson's disease.
    Med Lett Drugs Ther; 1989 Sep; 31(800):81-3. PubMed ID: 2505028
    [No Abstract]   [Full Text] [Related]  

  • 13. Retention rate of selegiline in early Parkinson's disease: a retrospective survey.
    Keränen T; Mattila T; Luukkaala T; Kuusisto H
    Int J Clin Pract; 2012 Oct; 66(10):1014. PubMed ID: 22994335
    [No Abstract]   [Full Text] [Related]  

  • 14. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Ben-Shlomo Y; Lees A;
    Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
    [No Abstract]   [Full Text] [Related]  

  • 15. Selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with selegiline in the treatment of Parkinson's disease.
    Poewe W; Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1987; 25():131-5. PubMed ID: 3123599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selegiline in Parkinson's disease; symptomatic or causal effect?].
    Wolters EC; Kuiper MA; Horstink MW
    Ned Tijdschr Geneeskd; 1992 Aug; 136(32):1544-7. PubMed ID: 1528279
    [No Abstract]   [Full Text] [Related]  

  • 18. Selegiline, pregnancy, and Parkinson's disease.
    Kupsch A; Oertel WH
    Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
    [No Abstract]   [Full Text] [Related]  

  • 19. MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987.
    J Neural Transm Suppl; 1987; 25():1-197. PubMed ID: 3123595
    [No Abstract]   [Full Text] [Related]  

  • 20. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.